SCHEMBL14930231

SCHEMBL14930231

CCC(CC(=O)Cl)OC(C)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 2/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
HRH1 P35367 1/20 0.40
KMT2A Q03164 1/20 0.40
TSHR P16473 3/20 0.37
SLC18A3 Q16572 1/20 0.35
ALOX15 P16050 1/20 0.34
PRKCA P17252 2/20 0.34
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM1 P11229 1/20 0.33
TBXA2R P21731 1/20 0.33
GALR3 O60755 1/20 0.32
MAPT P10636 1/20 0.32
BLM P54132 1/20 0.32
ALDH1A1 P00352 2/20 0.32
HSD17B10 Q99714 1/20 0.32
MMP12 P39900 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1584634 0.81
SCHEMBL4937252 0.81 SMN1; SMN2 (0.39) SMN1; SMN2LMNAMEN1CYP1A2HRH1
SCHEMBL4937258 0.81 SMN1; SMN2 (0.39) SMN1; SMN2LMNAMEN1CYP1A2HRH1
SCHEMBL4940791 0.81 SMN1; SMN2 (0.39) SMN1; SMN2LMNAMEN1CYP1A2HRH1
SCHEMBL10414980 0.80 LMNA (0.60) SMN1; SMN2LMNAMEN1CYP1A2HRH1
SCHEMBL27657335 0.78 SMN1; SMN2 (0.40) SMN1; SMN2LMNAMEN1CYP1A2HRH1
SCHEMBL17266054 0.78 MEN1 (0.37) SMN1; SMN2LMNAMEN1CYP1A2HRH1
SCHEMBL15132973 0.78 MEN1 (0.68) SMN1; SMN2LMNAMEN1CYP1A2HRH1
SCHEMBL9743514 0.77 MGAM (0.39) SMN1; SMN2LMNAMEN1CYP1A2HRH1
Hydrochloric Acid SCHEMBL17257584 0.76 LMNA (0.71) SMN1; SMN2LMNAMEN1CYP1A2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334235-B2 Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging PHENOMENOME DISCOVERIES INC. (CA) 2016-05-10 US disclosed
US-20130116312-A2 PLASMALOGEN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING DISEASES OF THE AGING PHENOMENOME DISCOVERIES INC. (CA) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116312-A2 PLASMALOGEN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING DISEASES OF THE AGING PHOSPHO1, SGMS2, MBOAT1 SMN1; SMN2 342/4885LMNA 1183/4885MEN1 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.